BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21212410)

  • 1. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
    Rushworth SA; Bowles KM; MacEwan DJ
    Cancer Res; 2011 Mar; 71(5):1999-2009. PubMed ID: 21212410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.
    Pullarkat V; Meng Z; Tahara SM; Johnson CS; Kalra VK
    Hemoglobin; 2014; 38(3):188-95. PubMed ID: 24670032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.
    Chen Z; Pittman EF; Romaguera J; Fayad L; Wang M; Neelapu SS; McLaughlin P; Kwak L; McCarty N
    PLoS One; 2013; 8(8):e69126. PubMed ID: 23936317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.
    Fang J; Rhyasen G; Bolanos L; Rasch C; Varney M; Wunderlich M; Goyama S; Jansen G; Cloos J; Rigolino C; Cortelezzi A; Mulloy JC; Oliva EN; Cuzzola M; Starczynowski DT
    Blood; 2012 Jul; 120(4):858-67. PubMed ID: 22685174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
    Corrales-Medina FF; Manton CA; Orlowski RZ; Chandra J
    Leuk Res; 2015 Mar; 39(3):371-9. PubMed ID: 25612941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.
    Matondo M; Bousquet-Dubouch MP; Gallay N; Uttenweiler-Joseph S; Recher C; Payrastre B; Manenti S; Monsarrat B; Burlet-Schiltz O
    Leuk Res; 2010 Apr; 34(4):498-506. PubMed ID: 19811823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
    Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B
    Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of bortezomib-adapted I-45 mesothelioma cells.
    Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
    Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
    Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antioxidant-induced phosphorylation of tyrosine 486 leads to rapid nuclear export of Bach1 that allows Nrf2 to bind to the antioxidant response element and activate defensive gene expression.
    Kaspar JW; Jaiswal AK
    J Biol Chem; 2010 Jan; 285(1):153-62. PubMed ID: 19897490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
    Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
    PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells.
    Carter BZ; Mak DH; Wang Z; Ma W; Mak PY; Andreeff M; Davis RE
    Leuk Res; 2013 Aug; 37(8):974-9. PubMed ID: 23669290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells.
    Du ZX; Yan Y; Zhang HY; Liu BQ; Gao YY; Niu XF; Meng X; Wang HQ
    J Clin Endocrinol Metab; 2011 May; 96(5):E763-71. PubMed ID: 21346076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P; Galán-Malo P; Marzo I; Naval J
    Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
    Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
    Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bach1 differentially regulates distinct Nrf2-dependent genes in human venous and coronary artery endothelial cells adapted to physiological oxygen levels.
    Chapple SJ; Keeley TP; Mastronicola D; Arno M; Vizcay-Barrena G; Fleck R; Siow RCM; Mann GE
    Free Radic Biol Med; 2016 Mar; 92():152-162. PubMed ID: 26698668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
    Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
    Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
    Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.